January 30, 2019 - ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell imaging agent. The trial will enroll metastatic cancer patients and will study the correlation of imaging signals observed using ImaginAb’s CD8+ T cell ImmunoPET imaging agent, standard-of-care scans and immunohistochemistry analysis of CD8 in biopsied tissues. The trial will also measure changes in CD8+ T-cell distribution before and after immuno-oncology therapies. The study is, in part, financially supported by Boehringer Ingelheim and contributes to the aims of the strategic collaboration between ImaginAb and Boehringer Ingelheim to develop ImaginAb’s CD8+ T cell Immuno-PET imaging agent, IAB22M2C.
IAB22M2C is designed to be used with positron emission tomography (PET) scan technology to non-invasively measure CD8+ T cell tumor infiltrates in patients with cancer, including the identification of changes in CD8+ T cell tumor infiltrates induced by immuno-oncology treatments. This investigational approach has the potential to guide the development of immunomodulatory agents and combinations by assessing whether a patient’s immune system responds to such agents, thereby offering an early prediction of therapeutic response.
The Phase II trial follows on the heels of a recently completed Phase I study which, according to ImaginAb, showed an excellent safety profile and encouraging preliminary efficacy of the radiotracer.
For more information: www.imaginab.com
October 19, 2026 
